312 related articles for article (PubMed ID: 8885581)
1. Regulatory issues in pediatric psychopharmacology.
Laughren TP
J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
[TBL] [Abstract][Full Text] [Related]
2. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
Buck ML
Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
[No Abstract] [Full Text] [Related]
3. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
4. Psychopharmacology. The medication merry-go-round.
Brown K
Science; 2003 Mar; 299(5613):1646-9. PubMed ID: 12637713
[No Abstract] [Full Text] [Related]
5. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
6. Traditional and alternative research designs and methods in clinical pediatric psychopharmacology.
Fava M
J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1292-303. PubMed ID: 8885583
[TBL] [Abstract][Full Text] [Related]
7. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
8. Pediatric research: coming of age in the new millennium.
Milne CP
Am J Ther; 1999 Sep; 6(5):263-82. PubMed ID: 11329108
[TBL] [Abstract][Full Text] [Related]
9. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
Field MJ; Ellinger LK; Boat TF
Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
[TBL] [Abstract][Full Text] [Related]
10. [The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations].
Kölch M; Lippert HD; Fegert JM
Z Kinder Jugendpsychiatr Psychother; 2006 Mar; 34(2):117-26. PubMed ID: 16610597
[TBL] [Abstract][Full Text] [Related]
11. Advances in pediatric pharmacology, therapeutics, and toxicology.
Berlin CM
Adv Pediatr; 2001; 48():439-64. PubMed ID: 11480767
[TBL] [Abstract][Full Text] [Related]
12. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
13. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
Baghdadli A; Gonnier V; Aussilloux C
Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
15. Practical clinical issues regarding child and adolescent psychopharmacology.
Kutcher S
Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):245-60. PubMed ID: 10674199
[TBL] [Abstract][Full Text] [Related]
16. Uses of drugs not described in the package insert (off-label uses).
Committee on Drugs. American Academy of Pediatrics
Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968
[TBL] [Abstract][Full Text] [Related]
17. Challenges and opportunities in bringing new medications to market for pediatric patients.
Upadhyaya HP; Gault L; Allen AJ
J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
[No Abstract] [Full Text] [Related]
18. Review of safety assessment methods used in pediatric psychopharmacology.
Greenhill LL; Vitiello B; Riddle MA; Fisher P; Shockey E; March JS; Levine J; Fried J; Abikoff H; Zito JM; McCracken JT; Findling RL; Robinson J; Cooper TB; Davies M; Varipatis E; Labellarte MJ; Scahill L; Walkup JT; Capasso L; Rosengarten J
J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):627-33. PubMed ID: 12921469
[TBL] [Abstract][Full Text] [Related]
19. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
[TBL] [Abstract][Full Text] [Related]
20. FDA Modernization Act: implications for oncology.
Morris L
Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
